Repligen
RGEN
A$178.92
Share price
-0.53%
Change (1 day)
-28.13%
Change (1 year)
Categories
Revenue for Repligen (RGEN)
Revenue in 2025 (TTM): A$1.00 Billion
According to Repligen
's latest financial reports the company's current revenue (TTM 
) is A$1.00 Billion. In 2024 the company made a revenue of A$1.01 Billion an increase over the revenue in the year 2023 that were of A$0.91 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Repligen from 1996 to 2025
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2025 (TTM) | A$1.00 B | -1.73% |
| 2024 | A$1.01 B | 11.82% |
| 2023 | A$0.91 B | -22.55% |
| 2022 | A$1.17 B | 27.35% |
| 2021 | A$0.92 B | 94.17% |
| 2020 | A$0.47 B | 23.4% |
| 2019 | A$0.38 B | 40.14% |
| 2018 | A$0.27 B | 52.25% |
| 2017 | A$0.18 B | 24.74% |
| 2016 | A$0.14 B | 26.47% |
| 2015 | A$0.11 B | 47.68% |
| 2014 | A$77.64 M | 1.6% |
| 2013 | A$76.42 M | 27.55% |
| 2012 | A$59.91 M | |
| 2010 | A$25.84 M | 12.22% |
| 2009 | A$23.03 M | -42.1% |
| 2008 | A$39.78 M | 76.61% |
| 2007 | A$22.52 M | 33.91% |
| 2006 | A$16.82 M | -5.47% |
| 2005 | A$17.79 M | 62.41% |
| 2004 | A$10.95 M | 18.92% |
| 2003 | A$9.21 M | -28.36% |
| 2002 | A$12.86 M | 80.78% |
| 2001 | A$7.11 M | 48.57% |
| 2000 | A$4.78 M | -8.57% |
| 1999 | A$5.23 M | 33.62% |
| 1998 | A$3.91 M | -11.94% |
| 1997 | A$4.45 M | -6.95% |
| 1996 | A$4.78 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Novavax NVAX | A$1.87 B | 86.74% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | A$4.55 B | 353.58% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | A$3.87 B | 285.88% | 🇺🇸 USA |
 General Electric GE | A$64.24 B | 6,297.16% | 🇺🇸 USA |
 Thermo Fisher Scientific TMO | A$66.23 B | 6,495.34% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | A$73.65 B | 7,234.24% | 🇺🇸 USA |
 Pfizer PFE | A$96.44 B | 9,503.35% | 🇺🇸 USA |
 Bio-Techne TECH | A$1.86 B | 85.84% | 🇺🇸 USA |
 Sangamo Therapeutics
SGMO | A$98.43 M | -90.20% | 🇺🇸 USA |
 Charles River Laboratories
CRL | A$6.21 B | 518.45% | 🇺🇸 USA |